Ensho Joins Race To Develop An Oral Integrin Inhibitor For IBD

Start-Up Licensed Lead Drug From Eisai Subsidiary

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Ensho Therapeutics is raising series A cash to develop Phase II-ready NSHO-101 (EA1080), a third oral ɑ4β7 integrin inhibitor attempting to take on Takeda’s blockbuster injectable Entyvio.

Rocket launching from wood cube with business icon, Start-up, Creativity, Big idea, Business goals management, Investment
Ensho is launching with a new CEO coming from Telavant • Source: Shutterstock

Ensho Therapeutics Inc. launched on 27 June to announce that it will start Phase II clinical trials in ulcerative colitis (UC) during the first half of 2025 for lead drug candidate NSHO-101 (EA1080), an oral alpha-4 beta-7 (ɑ4β7) integrin inhibitor licensed from Eisai Co., Ltd.’s gastrointestinal disease subsidiary EA Pharma Co., Ltd.

Key Takeaways

  • Ensho Therapeutics launched with an oral ɑ4β7 integrin inhibitor, NSHO-101 (EA1080), licensed from Eisai subsidiary EA Pharma and the company is in the middle of raising a series A round.

At least two other companies already have oral drugs in Phase II against the same target, each hoping to grab...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Partnered By

Nancy Testing Partnered Content

This is a short description.

Pierre Fabre Pushes To Be Partner Of Choice For Budding Biotechs

 
• By Kevin Grogan

Francesco Hofmann, head of R&D at the mid-sized French group, tells Scrip that its strategy of not playing in the spaces that are dominated by big pharma is paying off.

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.